[Mechanism of action of old and new anticoagulants]

Simon F Stämpfli1, Lars M Asmis, Felix C Tanner

  • 1Kardiovaskuläre Forschung, Physiologisches Institut, Universität Zürich, Schweiz.

Herz
|February 15, 2008
PubMed

Insights

Anticoagulant therapy is crucial for common conditions like atrial fibrillation but carries bleeding risks. Understanding coagulation mechanisms is key to balancing effective anticoagulation with patient safety.

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Context:

  • Anticoagulants are widely prescribed for atrial fibrillation, venous thromboembolism, and valvular heart disease, affecting approximately 1% of the population.
  • Vitamin K antagonists are used in about one-third of patients in surgical clinics, highlighting the frequent clinical encounters with anticoagulatory treatments.

Purpose:

  • To provide a comprehensive overview of the coagulation system.
  • To discuss established and emerging pharmacological targets for anticoagulation therapy.

Summary:

  • Anticoagulant therapy offers significant benefits but carries an increased risk of bleeding, necessitating careful management.
  • Optimizing anticoagulation requires balancing hemostasis with the prevention of thrombus formation.
  • Understanding the mechanisms of anticoagulation is key for effective clinical practice.

Impact:

  • Enhances clinical decision-making for general practitioners and specialists managing anticoagulated patients.
  • Facilitates a deeper understanding of anticoagulant mechanisms, leading to improved patient outcomes.
  • Informs the development and application of novel anticoagulation strategies.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...